Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | ERCC1 | P07992 | 4/20 | 0.61 |
| ▸ | ERCC4 | Q92889 | 4/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | P2RX7 | Q99572 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17372538 | 0.87 | ALDH1A1 (0.61) | ALDH1A1ERCC1ERCC4NPC1RAB9A | |
| SCHEMBL4246819 | 0.86 | P2RX7 (0.54) | ALDH1A1ERCC1ERCC4NPC1RAB9A | |
| SCHEMBL7241336 | 0.85 | ALDH1A1 (0.62) | ALDH1A1ERCC1ERCC4NPC1RAB9A | |
| SCHEMBL4038474 | 0.85 | HPGD (0.69) | ALDH1A1LMNAMAPTCNR1 | |
| SCHEMBL17914676 | 0.85 | ALDH1A1 (0.62) | ALDH1A1ERCC1ERCC4NPC1RAB9A | |
| SCHEMBL1143378 | 0.85 | ALDH1A1 (0.62) | ALDH1A1ERCC1ERCC4NPC1RAB9A | |
| SCHEMBL23565573 | 0.83 | ERCC1 (0.58) | ALDH1A1ERCC1ERCC4NPC1RAB9A | |
| SCHEMBL12354898 | 0.83 | ALDH1A1 (0.74) | ALDH1A1ERCC1ERCC4NPC1RAB9A | |
| SCHEMBL23565221 | 0.83 | P2RX7 (0.59) | ALDH1A1ERCC1ERCC4NPC1RAB9A | |
| SCHEMBL697972 | 0.82 | ALDH1A1 (0.63) | ALDH1A1ERCC1ERCC4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5834514-A | INHIBITORS OF INTERLEUKIN-1B CONVERTING ENZYME, TREATMENT OF INFLAMMATORY AND IMMUNE BASED DISEASES OF THE LUNGS, CENTRAL NERVOUS SYSTEM AND CONNECTIVE TISSUES | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1998-11-10 | — | — | US | claimed |
| EP-0758891-A4 | HALOMETHYL AMIDES AS IL-1-g(b) PROTEASE INHIBITORS | SANOFI WINTHROP INC (US) | 1997-12-03 | — | — | EP | claimed |
| EP-0758891-A1 | HALOMETHYL AMIDES AS IL-1$g(b) PROTEASE INHIBITORS | SANOFI WINTHROP, INC. (US) | 1997-02-26 | — | — | EP | claimed |
| WO-1995029672-A1 | HALOMETHYL AMIDES AS IL-1β PROTEASE INHIBITORS | SANOFI WINTHROP, INC. (US) | 1995-11-09 | — | — | WO | claimed |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | ABSOLUTE SCIENCE, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | ABSOLUTE SCIENCE, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| EP-2337778-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | Absolute Science, INC. (US) | 2011-06-29 | — | — | EP | disclosed |
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| EP-2190293-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | Absolute Science, INC. (US) | 2010-06-02 | — | — | EP | disclosed |
| WO-2010033360-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | 1/3 ABSOLUTE SCIENCE, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2010033360-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | 1/3 ABSOLUTE SCIENCE, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| US-7407960-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2008-08-05 | — | — | US | disclosed |
| EP-1806346-A1 | Substituted piperazine compounds and their use as fatty acid oxidation inhibitors | CV THERAPEUTICS, INC. (US) | 2007-07-11 | — | — | EP | disclosed |
| US-20070004751-A1 | Substituted heterocyclic compounds | ELZEIN ELFATIH | 2007-01-04 | — | — | US | disclosed |
| US-7125876-B2 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. (US) | 2006-10-24 | — | — | US | disclosed |
| EP-1567525-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2005-08-31 | — | — | EP | disclosed |
| US-20040152890-A1 | Substituted heterocyclic compounds | CV THERAPEUTICS, INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004052887-A2 | SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2004-06-24 | — | — | WO | disclosed |
| US-5834514-A | INHIBITORS OF INTERLEUKIN-1B CONVERTING ENZYME, TREATMENT OF INFLAMMATORY AND IMMUNE BASED DISEASES OF THE LUNGS, CENTRAL NERVOUS SYSTEM AND CONNECTIVE TISSUES | VERTEX PHARMACEUTICALS, INCORPORATED (US) | 1998-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | MMP7, MMP3, MMP9 | ALDH1A1 496/4885ERCC1 2534/4885ERCC4 706/4885 |
| US-20040152890-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | ALDH1A1 245/4885ERCC1 3886/4885ERCC4 4199/4885 |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | NPY5R, RAC3, CPA3 | ALDH1A1 2213/4885ERCC1 4122/4885ERCC4 3016/4885 |
| US-20070004751-A1 | Substituted heterocyclic compounds | KCNH1, SDHA, COQ8A | ALDH1A1 281/4885ERCC1 3668/4885ERCC4 3926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.